MA33976B1 - Spiroindolinone pyrrolidines - Google Patents

Spiroindolinone pyrrolidines

Info

Publication number
MA33976B1
MA33976B1 MA34939A MA34939A MA33976B1 MA 33976 B1 MA33976 B1 MA 33976B1 MA 34939 A MA34939 A MA 34939A MA 34939 A MA34939 A MA 34939A MA 33976 B1 MA33976 B1 MA 33976B1
Authority
MA
Morocco
Prior art keywords
spiroindolinone
pyrrolidines
compounds
spiroindolinone pyrrolidines
simulations
Prior art date
Application number
MA34939A
Other languages
Arabic (ar)
English (en)
Inventor
David Joseph Bartkovitz
Xin-Jie Chu
Qingjie Ding
Bradford James Graves
Nan Jiang
Jing Zhang
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33976B1 publication Critical patent/MA33976B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne des composés de la formule (i) dans laquelle x, y et r1 à r8 sont décrits par les présentes ainsi que les énantiomères, les sels de qualité pharmaceutique et les esters de ceux-ci. Les composés sont utiles comme agents anticancéreux.
MA34939A 2009-12-02 2010-11-29 Spiroindolinone pyrrolidines MA33976B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26579209P 2009-12-02 2009-12-02
US38805410P 2010-09-30 2010-09-30
PCT/EP2010/068353 WO2011067185A1 (fr) 2009-12-02 2010-11-29 Spiroindolinone pyrrolidines

Publications (1)

Publication Number Publication Date
MA33976B1 true MA33976B1 (fr) 2013-02-01

Family

ID=43608656

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34939A MA33976B1 (fr) 2009-12-02 2010-11-29 Spiroindolinone pyrrolidines

Country Status (26)

Country Link
US (1) US8088815B2 (fr)
EP (1) EP2507243B1 (fr)
JP (1) JP5647262B2 (fr)
KR (1) KR101418191B1 (fr)
CN (1) CN102741257B (fr)
AR (1) AR079226A1 (fr)
AU (1) AU2010326855B2 (fr)
BR (1) BR112012012872A2 (fr)
CA (1) CA2781823A1 (fr)
CL (1) CL2012001405A1 (fr)
CO (1) CO6541606A2 (fr)
CR (1) CR20120259A (fr)
EC (1) ECSP12011945A (fr)
ES (1) ES2543468T3 (fr)
IL (1) IL220010A (fr)
MA (1) MA33976B1 (fr)
MX (1) MX2012006260A (fr)
MY (1) MY160596A (fr)
NZ (1) NZ600024A (fr)
PE (1) PE20121334A1 (fr)
PH (1) PH12012501029A1 (fr)
RU (1) RU2571100C2 (fr)
SG (1) SG181465A1 (fr)
TW (1) TW201129571A (fr)
WO (1) WO2011067185A1 (fr)
ZA (1) ZA201204036B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2118123B1 (fr) * 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Peptides p53 stabilises et utilisations de ceux-ci
EP2508531B1 (fr) 2007-03-28 2016-10-19 President and Fellows of Harvard College Polypeptides piqués
KR20120099462A (ko) * 2009-11-12 2012-09-10 더 리젠츠 오브 더 유니버시티 오브 미시건 스피로-옥신돌 ｍｄｍ2 길항제
US20110118283A1 (en) * 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8288431B2 (en) * 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
US20120046306A1 (en) * 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
AU2011326395B2 (en) 2010-11-12 2016-01-07 Ascenta Licensing Corporation Spiro-oxindole MDM2 antagonists
TR201807311T4 (tr) * 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
ES2624808T3 (es) 2011-05-11 2017-07-17 The Regents Of The University Of Michigan Antagonistas de MDM2 espirooxindólicos
WO2013049250A1 (fr) 2011-09-27 2013-04-04 Amgen Inc. Heterocycles utilises comme inhibiteurs de mdm2 dans le traitement du cancer
MX358886B (es) 2011-10-18 2018-08-31 Aileron Therapeutics Inc Macrociclos peptidomimeticos.
CN107216380A (zh) 2012-02-15 2017-09-29 爱勒让治疗公司 拟肽大环化合物
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
CN103113854B (zh) * 2013-02-06 2015-11-18 青岛奥环新能源科技发展有限公司 一种移动供热用复合相变材料及其制备方法
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
CN105121407B (zh) * 2013-02-28 2017-07-18 美国安进公司 用于治疗癌症的苯甲酸衍生物mdm2抑制剂
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
PE20160113A1 (es) 2013-06-10 2016-03-03 Amgen Inc Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2
CN103342672B (zh) * 2013-07-02 2015-12-23 扬州大学 取代吡咯烷-2-酮的新合成方法
KR102389552B1 (ko) 2014-04-17 2022-04-22 더 리젠츠 오브 더 유니버시티 오브 미시간 Mdm2 저해제 및 이 저해제를 사용하는 치료 방법
JP6503386B2 (ja) 2014-07-03 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体
CN105829318B (zh) * 2014-08-18 2018-10-02 哈德森生物医药有限公司 作为mdm2抑制剂的螺吡咯烷
CA2956129C (fr) 2014-08-21 2022-10-25 Boehringer Ingelheim International Gmbh Nouveaux composes spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one et derives en tant qu'inhibiteurs de mdm2-p53
CN112972378A (zh) 2014-09-24 2021-06-18 艾瑞朗医疗公司 拟肽大环化合物及其制剂
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
RU2629750C2 (ru) * 2015-04-09 2017-09-01 Ян Андреевич Иваненков НОВЫЕ ДИСПИРО-ИНДОЛИНОНЫ, ИНГИБИТОРЫ MDM2/p53 ВЗАИМОДЕЙСТВИЯ, СПОСОБ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
PL3359542T3 (pl) 2015-10-09 2021-09-20 Boehringer Ingelheim International Gmbh Związki i pochodne spiro[3h-indolo-3,2’-pirolidyno]-2(1h)-onowe jako inhibitory mdm2-p53
GB201603779D0 (en) * 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
CN105949221B (zh) * 2016-05-11 2017-08-25 湖南科技大学 一种含螺吲哚‑2‑酮衍生物及其制备方法和作为抗癌药物的应用
EP3458101B1 (fr) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Conjugués anticorps-protac et procédés d'utilisation
US10471154B2 (en) 2016-08-08 2019-11-12 Fei Xiao Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
EP3511334A1 (fr) * 2018-01-16 2019-07-17 Adamed sp. z o.o. Composés de 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole] -2,3'-dione comme agents thérapeutiques activant le tp53
RU2730287C1 (ru) * 2019-08-30 2020-08-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Новые 2',5'-диарилспиро[индол-3,3'-пирролидин]-2(1н)-оны и способ их получения
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
JP2023539867A (ja) 2020-08-27 2023-09-20 大塚製薬株式会社 Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー
US12569564B2 (en) 2021-01-23 2026-03-10 Newave Pharmaceutical Inc. Spirocyclic MDM2 modulator and uses thereof
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
CN115215872A (zh) * 2021-04-15 2022-10-21 中国科学院上海药物研究所 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物
US12398147B2 (en) 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
CN113387957B (zh) * 2021-06-09 2022-08-09 江苏亚尧生物科技有限公司 螺环吲哚酮-吡咯烷碳酸酯化合物和其组合物、制备方法及用途
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023056069A1 (fr) 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation
WO2023086400A1 (fr) * 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux dérivés de spiropyrrolidine
WO2023107419A1 (fr) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Composés spirocycliques saturés utilisés comme agents antiviraux
CN116283701B (zh) * 2021-12-21 2025-04-22 中国科学院上海药物研究所 具有4-(取代氨甲基)-5-新戊基-n-取代基吡咯烷-2-甲酰胺结构的化合物
CN114773327B (zh) * 2022-04-18 2023-08-18 广东优康精细化工有限公司 一种吡噻菌胺中间体的制备方法
WO2024240858A1 (fr) 2023-05-23 2024-11-28 Valerio Therapeutics Molécules protac dirigées contre un système de réparation de dommages à l'adn et leurs utilisations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2759935A (en) * 1953-02-18 1956-08-21 Bristol Lab Inc Substituted 3-phenyloxindoles
US3441570A (en) * 1966-01-20 1969-04-29 Parke Davis & Co 3-tertiary aminoalkylamino-3-phenyl oxindole compounds
US3686210A (en) * 1970-01-13 1972-08-22 American Home Prod 2-acylamido-3-aryl-3h-indol-3-ol esters and related compounds
US4020179A (en) * 1975-05-15 1977-04-26 Richardson-Merrell Inc. 7-Substituted-2-indolinones
JPS55129284A (en) 1979-03-27 1980-10-06 Shionogi & Co Ltd 3-(1-imipazolyl)indolin-2-one
DE3714473A1 (de) 1987-04-30 1988-11-10 Basf Ag Kontinuierliches verfahren zur epimerisierung von zuckern, insbesondere von d-arabinose zu d-ribose
RU2084449C1 (ru) * 1994-03-02 1997-07-20 Всероссийский научный центр по безопасности биологически активных веществ 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
WO1998054167A1 (fr) 1997-05-28 1998-12-03 Mitsubishi-Tokyo Pharmaceuticals, Inc. Composes d'indole
US6511974B1 (en) * 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
EP0947511A1 (fr) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Dérivés de l'acide phénoxyacétique et de phénoxyméthyltétrazole ayant une activité antitumorale
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
JP2000191661A (ja) 1998-12-25 2000-07-11 Mitsubishi-Tokyo Pharmaceuticals Inc 環状アミド化合物
DK1183033T3 (da) 1999-05-21 2006-06-06 Bristol Myers Squibb Co Pyrrolotriazininhibitorer af kinaser
CZ2002203A3 (cs) 1999-07-21 2002-08-14 Astrazeneca Ab Spirooxindolové deriváty
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US7250442B2 (en) 2002-03-15 2007-07-31 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
DE202004014849U1 (de) * 2004-09-23 2005-02-03 Trw Automotive Safety Systems Gmbh Vorrichtung zur Bestimmung eines absoluten Drehwinkels
US8030499B2 (en) 2005-01-28 2011-10-04 Taisho Pharmaceutical Co., Ltd. 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
AU2006216780B8 (en) * 2005-02-22 2010-04-22 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and uses thereof
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
KR101052706B1 (ko) 2006-03-13 2011-08-01 에프. 호프만-라 로슈 아게 스피로인돌리논 유도체
US7495007B2 (en) * 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
KR20090042779A (ko) 2006-06-30 2009-04-30 쉐링 코포레이션 Ｐ53 활성을 증가시키는 치환된 피페리딘 및 이의 사용
US7737174B2 (en) * 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
BRPI0715506A2 (pt) 2006-08-30 2014-07-08 Univ Michigan Novas moléculas pequenas inibidoras de mdm2 e usos das mesmas
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2008080822A1 (fr) 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Méthodologies d'épimérisation permettant le recueil de stéréoisomères très purs avec un bon rendement
US7553833B2 (en) * 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
KR101380013B1 (ko) * 2008-09-18 2014-04-10 에프. 호프만-라 로슈 아게 치환 피롤리딘-2-카르복사미드
KR20120099462A (ko) * 2009-11-12 2012-09-10 더 리젠츠 오브 더 유니버시티 오브 미시건 스피로-옥신돌 ｍｄｍ2 길항제
RU2012147597A (ru) * 2010-04-09 2014-05-20 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Биомаркеры для ингибиторов mdm2, использующиеся для лечения заболевания

Also Published As

Publication number Publication date
CL2012001405A1 (es) 2012-09-28
CA2781823A1 (fr) 2011-06-09
SG181465A1 (en) 2012-07-30
CO6541606A2 (es) 2012-10-16
MY160596A (en) 2017-03-15
RU2571100C2 (ru) 2015-12-20
ECSP12011945A (es) 2012-07-31
US8088815B2 (en) 2012-01-03
ES2543468T3 (es) 2015-08-19
KR101418191B1 (ko) 2014-07-09
HK1173720A1 (en) 2013-05-24
CR20120259A (es) 2012-07-12
ZA201204036B (en) 2013-02-27
AU2010326855B2 (en) 2015-10-29
NZ600024A (en) 2014-08-29
TW201129571A (en) 2011-09-01
JP2013512869A (ja) 2013-04-18
CN102741257A (zh) 2012-10-17
PH12012501029A1 (en) 2013-01-14
PE20121334A1 (es) 2012-10-12
IL220010A0 (en) 2012-07-31
EP2507243A1 (fr) 2012-10-10
CN102741257B (zh) 2015-03-04
AU2010326855A1 (en) 2012-06-21
JP5647262B2 (ja) 2014-12-24
KR20120101481A (ko) 2012-09-13
BR112012012872A2 (pt) 2017-10-10
RU2012125763A (ru) 2014-01-10
MX2012006260A (es) 2012-06-19
EP2507243B1 (fr) 2015-06-10
US20110130398A1 (en) 2011-06-02
WO2011067185A1 (fr) 2011-06-09
AR079226A1 (es) 2012-01-04
IL220010A (en) 2014-03-31

Similar Documents

Publication Publication Date Title
MA33976B1 (fr) Spiroindolinone pyrrolidines
JOP20180103A1 (ar) مركب صيدلاني
UA111770C2 (uk) Інгібітори бромдомену
UA107954C2 (xx) Заміщені піролідин-2-карбоксаміди
EA201390934A1 (ru) Композиции и способы модулирования fxr
IN2014MN02598A (fr)
EA201101618A1 (ru) Арилпиридины в качестве ингибиторов альдостеронсинтазы
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
MX336381B (es) Boronatos como inhibidores de arginasa.
IN2014CN04530A (fr)
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
CR20120641A (es) Compuestos macrocìclicos como inhibidores de quinasa trk
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
SV2011003855A (es) Heteroarilos sustituidos
IN2015DN01119A (fr)
EA201270216A1 (ru) Фармацевтический состав
MX2013006802A (es) Inhibidores de neprilisina.
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
MD4556B1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
IN2012DN03182A (fr)
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.